In line with this, by exploring the glioma public database, we observed that HSP90B1 was most highly expressed in the most malignant mesenchymal subtype gliomas, and that patients with higher HSP90B1 expression had a poorer prognosis. This evidence concerns the gene HSP90B1 and glioma.